Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Orchestra BioMed Holdings Inc. (OBIO)
Orchestra BioMed Holdings Inc. (NASDAQ:OBIO) has a market capitalization of $327.57 Million ($327.57 Million) as of September 25, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14526 globally and #3432 in its home market, demonstrating a -1.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orchestra BioMed Holdings Inc.'s stock price $5.95 by its total outstanding shares 60105049 (60.11 Million). Also see Orchestra BioMed Holdings Inc. balance sheet assets for a full breakdown of the balance sheet.
Orchestra BioMed Holdings Inc. Market Cap History: 2020 to 2026
Orchestra BioMed Holdings Inc.'s market capitalization history from 2020 to 2026. Data shows change from $769.95 Million to $357.63 Million (-10.04% CAGR). Also see Orchestra BioMed Holdings Inc. operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Orchestra BioMed Holdings Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.64 Trillion | 0.01% | #390 of 976 |
|
NASDAQ Composite
IXIC
|
$42.16 Trillion | 0.00% | #1404 of 3165 |
Weight: Orchestra BioMed Holdings Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Orchestra BioMed Holdings Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orchestra BioMed Holdings Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check OBIO stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
7.45x
Orchestra BioMed Holdings Inc.'s market cap is 7.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $769.95 Million | $5.70 Million | -$21.36 Million | 135.01x | N/A |
| 2021 | $605.86 Million | $-782.00K | -$23.01 Million | -774.76x | N/A |
| 2022 | $599.85 Million | $3.53 Million | -$33.61 Million | 169.78x | N/A |
| 2023 | $548.76 Million | $2.76 Million | -$49.12 Million | 198.83x | N/A |
| 2024 | $252.44 Million | $2.64 Million | -$61.02 Million | 95.69x | N/A |
| 2025 | $249.44 Million | $33.48 Million | -$52.70 Million | 7.45x | N/A |
Competitor Companies of OBIO by Market Capitalization
Companies near Orchestra BioMed Holdings Inc. in the global market cap rankings as of September 25, 2026. Review OBIO goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Orchestra BioMed Holdings Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #333 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #450 globally with a market cap of $61.49 Billion USD ( AU$86.90 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $522.38 |
| #333 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $796.02 |
| #450 | CSL Ltd | AU:CSL | $61.49 Billion | AU$179.12 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $194.82 |
Orchestra BioMed Holdings Inc. Historical Marketcap From 2020 to 2026
Between 2020 and today, Orchestra BioMed Holdings Inc.'s market cap moved from $769.95 Million to $ 357.63 Million, with a yearly change of -10.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $357.63 Million | +43.37% |
| 2025 | $249.44 Million | -1.19% |
| 2024 | $252.44 Million | -54.00% |
| 2023 | $548.76 Million | -8.52% |
| 2022 | $599.85 Million | -0.99% |
| 2021 | $605.86 Million | -21.31% |
| 2020 | $769.95 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 25th, 2026 the market cap of Orchestra BioMed Holdings Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $327.57 Million USD |
| MoneyControl | $327.57 Million USD |
| MarketWatch | $327.57 Million USD |
| marketcap.company | $327.57 Million USD |
| Reuters | $327.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more